{"success":true,"data":{"pressRelease":{"id":"42293","rtpr_id":"nPn1L9FL5a","ticker":"IMMP","exchange":"NASDAQ","all_tickers":["IMMP","IMM"],"title":"Lost Money on Immutep Limited (IMMP)? Join Class Action Suit Seeking Recovery - Contact SueWallSt","author":"PR Newswire","published_at":"2026-05-21T13:00:04.282Z","article_body":"Lost Money on Immutep Limited (IMMP)? Join Class Action Suit Seeking Recovery - Contact SueWallSt\n\nPR Newswire\n\nNEW YORK, May 21, 2026\n\nImmutep's CEO, Chief Scientific Officer, and Chief Medical Officer Face\nSection 20(a) Control Person Claims After TACTI-004 Trial Collapse Cost\nShareholders $2.28 Per Share\n\nNEW YORK, May 21, 2026 /PRNewswire/ -- SueWallSt alerts investors in Immutep\nLimited (NASDAQ: IMMP) that three senior executives are named as individual\ndefendants in a securities class action covering purchases between March 24,\n2025 and March 12, 2026. Find out if you qualify to recover losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-8&h=4145619841&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fimmutep-limited-class-action-lawsuit-immp%3Fprid%3D186211%26wire%3D4&a=Find+out+if+you+qualify+to+recover+losses)\n or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\n(https://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.html)\n\nImmutep ADRs fell from $2.76 to $0.48 per share on March 13, 2026, an 83%\nsingle-day decline of $2.28 per share. The Court has set July 6, 2026 as the\ndeadline to apply for lead plaintiff appointment.\n\nThe Named Individual Defendants\n\nThe complaint identifies three officers who allegedly exercised control over\nImmutep's public statements and SEC filings throughout the Class Period:\n\n * Marc Voigt, Executive Director and Chief Executive Officer, who oversaw all\ncorporate communications and signed Company filings with the SEC\n * Frédéric Triebel, Executive Director and Chief Scientific Officer, who\ndirected efti's clinical development strategy and publicly vouched for\nTACTI-004's scientific foundation\n * Stephan Winckels, Chief Medical Officer, who managed clinical trial operations\nand provided public commentary on investigator feedback and trial design\nThe action contends each defendant possessed the power and authority to\ncontrol the contents of Immutep's SEC reports, press releases, and\npresentations to analysts and institutional investors.\n\nSection 20(a) Control Person Framework\n\nSection 20(a) of the Securities Exchange Act imposes liability on every person\nwho directly or indirectly controls any person liable under Section 10(b). The\ncomplaint alleges that each Individual Defendant:\n\n * Had access to material non-public information regarding TACTI-004's internal\nclinical data and interim analyses\n * Was provided with copies of the Company's reports and press releases prior to\nor shortly after issuance\n * Had the ability and opportunity to prevent the issuance of misleading\nstatements or cause them to be corrected\n * Knew that adverse facts had not been disclosed to the investing public\nSarbanes-Oxley Certification Obligations\n\nAs officers responsible for Immutep's SEC filings, the Individual Defendants\nbore personal certification obligations under Sections 302 and 906 of the\nSarbanes-Oxley Act. These certifications require signing officers to attest\nthat filings do not contain untrue statements of material fact or omit\nmaterial facts necessary to make the statements not misleading. The lawsuit\nasserts these certifications were made while defendants allegedly concealed\ninformation that materially increased the risk of TACTI-004's failure.\n\nScienter Allegations\n\nThe complaint charges that the Individual Defendants acted with scienter,\nmeaning they knew or were deliberately reckless in not knowing that their\npublic statements were materially misleading. As pleaded, defendants had\nactual knowledge of or access to non-public information concerning interim\nefficacy data from the TACTI-004 trial, including the likelihood that the\nstudy would not meet its primary endpoints. Despite this alleged knowledge,\nthey repeatedly told investors the trial exhibited \"strong operational\nprogress\" and was \"on track\" for key milestones.\n\n\"Corporate officers have a duty to ensure their companies' public statements\nare accurate and complete. When executives certify SEC filings and make\naffirmative statements about clinical trial progress, they accept personal\nresponsibility for the accuracy of those representations.\" -- Joseph E. Levi,\nEsq.\n\nSpeak with an attorney about recovering your IMMP losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-8&h=4203939657&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fimmutep-limited-class-action-lawsuit-immp%3Fprid%3D186211%26wire%3D4&a=Speak+with+an+attorney+about+recovering+your+IMMP+losses)\n or call (888) SueWallSt.\n\nWHY SUEWALLST -- Ranked in ISS Securities Class Action Services' Top 50 Report\nfor seven consecutive years, SueWallSt is a nationally recognized leader in\nshareholder rights litigation. With a team of over 70 professionals, the firm\nhas recovered hundreds of millions of dollars for investors.\n\nFrequently Asked Questions About the IMMP Lawsuit\n\nQ: Who are the defendants named in the IMMP lawsuit? A: The complaint names\nImmutep Limited and individual defendants Marc Voigt (CEO), Frédéric Triebel\n(Chief Scientific Officer), and Stephan Winckels (Chief Medical Officer), each\nof whom signed SEC filings or made public statements during the Class Period.\n\nQ: What is the IMMP lead plaintiff deadline? A: The deadline to apply for\nlead plaintiff appointment is July 6, 2026. This deadline applies only to\ninvestors seeking to serve as lead plaintiff. Class members who do not apply\nmay still participate in any recovery without taking action before this date.\n\nQ: What do IMMP investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt. No immediate action is\nrequired to remain eligible as a class member.\n\nQ: What if I already sold my IMMP shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the Class Period and sold at a loss may\nstill participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. You\nsubmit a claim form to receive your portion of recovery.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nCONTACT:\nSueWallSt\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/lost-money-on-immutep-limited-immp-join-class-action-suit-seeking-recovery---contact-suewallst-302778448.html\n(https://www.prnewswire.com/news-releases/lost-money-on-immutep-limited-immp-join-class-action-suit-seeking-recovery---contact-suewallst-302778448.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1L9FL5a","title":"Lost Money on Immutep Limited (IMMP)? Join Class Action Suit Seeking Recovery - Contact SueWallSt","author":"PR Newswire","ticker":"IMMP","created":"2026-05-21T13:00:04.282Z","tickers":["IMMP","IMM"],"exchange":"NASDAQ","article_body":"Lost Money on Immutep Limited (IMMP)? Join Class Action Suit Seeking Recovery - Contact SueWallSt\n\nPR Newswire\n\nNEW YORK, May 21, 2026\n\nImmutep's CEO, Chief Scientific Officer, and Chief Medical Officer Face\nSection 20(a) Control Person Claims After TACTI-004 Trial Collapse Cost\nShareholders $2.28 Per Share\n\nNEW YORK, May 21, 2026 /PRNewswire/ -- SueWallSt alerts investors in Immutep\nLimited (NASDAQ: IMMP) that three senior executives are named as individual\ndefendants in a securities class action covering purchases between March 24,\n2025 and March 12, 2026. Find out if you qualify to recover losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-8&h=4145619841&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fimmutep-limited-class-action-lawsuit-immp%3Fprid%3D186211%26wire%3D4&a=Find+out+if+you+qualify+to+recover+losses)\n or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\n(https://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.html)\n\nImmutep ADRs fell from $2.76 to $0.48 per share on March 13, 2026, an 83%\nsingle-day decline of $2.28 per share. The Court has set July 6, 2026 as the\ndeadline to apply for lead plaintiff appointment.\n\nThe Named Individual Defendants\n\nThe complaint identifies three officers who allegedly exercised control over\nImmutep's public statements and SEC filings throughout the Class Period:\n\n * Marc Voigt, Executive Director and Chief Executive Officer, who oversaw all\ncorporate communications and signed Company filings with the SEC\n * Frédéric Triebel, Executive Director and Chief Scientific Officer, who\ndirected efti's clinical development strategy and publicly vouched for\nTACTI-004's scientific foundation\n * Stephan Winckels, Chief Medical Officer, who managed clinical trial operations\nand provided public commentary on investigator feedback and trial design\nThe action contends each defendant possessed the power and authority to\ncontrol the contents of Immutep's SEC reports, press releases, and\npresentations to analysts and institutional investors.\n\nSection 20(a) Control Person Framework\n\nSection 20(a) of the Securities Exchange Act imposes liability on every person\nwho directly or indirectly controls any person liable under Section 10(b). The\ncomplaint alleges that each Individual Defendant:\n\n * Had access to material non-public information regarding TACTI-004's internal\nclinical data and interim analyses\n * Was provided with copies of the Company's reports and press releases prior to\nor shortly after issuance\n * Had the ability and opportunity to prevent the issuance of misleading\nstatements or cause them to be corrected\n * Knew that adverse facts had not been disclosed to the investing public\nSarbanes-Oxley Certification Obligations\n\nAs officers responsible for Immutep's SEC filings, the Individual Defendants\nbore personal certification obligations under Sections 302 and 906 of the\nSarbanes-Oxley Act. These certifications require signing officers to attest\nthat filings do not contain untrue statements of material fact or omit\nmaterial facts necessary to make the statements not misleading. The lawsuit\nasserts these certifications were made while defendants allegedly concealed\ninformation that materially increased the risk of TACTI-004's failure.\n\nScienter Allegations\n\nThe complaint charges that the Individual Defendants acted with scienter,\nmeaning they knew or were deliberately reckless in not knowing that their\npublic statements were materially misleading. As pleaded, defendants had\nactual knowledge of or access to non-public information concerning interim\nefficacy data from the TACTI-004 trial, including the likelihood that the\nstudy would not meet its primary endpoints. Despite this alleged knowledge,\nthey repeatedly told investors the trial exhibited \"strong operational\nprogress\" and was \"on track\" for key milestones.\n\n\"Corporate officers have a duty to ensure their companies' public statements\nare accurate and complete. When executives certify SEC filings and make\naffirmative statements about clinical trial progress, they accept personal\nresponsibility for the accuracy of those representations.\" -- Joseph E. Levi,\nEsq.\n\nSpeak with an attorney about recovering your IMMP losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-8&h=4203939657&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fimmutep-limited-class-action-lawsuit-immp%3Fprid%3D186211%26wire%3D4&a=Speak+with+an+attorney+about+recovering+your+IMMP+losses)\n or call (888) SueWallSt.\n\nWHY SUEWALLST -- Ranked in ISS Securities Class Action Services' Top 50 Report\nfor seven consecutive years, SueWallSt is a nationally recognized leader in\nshareholder rights litigation. With a team of over 70 professionals, the firm\nhas recovered hundreds of millions of dollars for investors.\n\nFrequently Asked Questions About the IMMP Lawsuit\n\nQ: Who are the defendants named in the IMMP lawsuit? A: The complaint names\nImmutep Limited and individual defendants Marc Voigt (CEO), Frédéric Triebel\n(Chief Scientific Officer), and Stephan Winckels (Chief Medical Officer), each\nof whom signed SEC filings or made public statements during the Class Period.\n\nQ: What is the IMMP lead plaintiff deadline? A: The deadline to apply for\nlead plaintiff appointment is July 6, 2026. This deadline applies only to\ninvestors seeking to serve as lead plaintiff. Class members who do not apply\nmay still participate in any recovery without taking action before this date.\n\nQ: What do IMMP investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt. No immediate action is\nrequired to remain eligible as a class member.\n\nQ: What if I already sold my IMMP shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the Class Period and sold at a loss may\nstill participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. You\nsubmit a claim form to receive your portion of recovery.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nCONTACT:\nSueWallSt\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/lost-money-on-immutep-limited-immp-join-class-action-suit-seeking-recovery---contact-suewallst-302778448.html\n(https://www.prnewswire.com/news-releases/lost-money-on-immutep-limited-immp-join-class-action-suit-seeking-recovery---contact-suewallst-302778448.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-21T13:00:04.298633246Z","server_sent_at_ms":1779368404298},"received_at":"2026-05-21T13:00:04.634Z","source_url":"https://www.prnewswire.com/news-releases/lost-money-on-immutep-limited-immp-join-class-action-suit-seeking-recovery---contact-suewallst-302778448.html"},"analysis":{"id":"31731","press_release_id":"42293","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"SueWallSt issued a press release soliciting investors in Immutep Limited (IMMP) to join a securities class action lawsuit.\n\nThe firm highlights that three senior executives—CEO Marc Voigt, CSO Frédéric Triebel, and CMO Stephan Winckels—are named as individual defendants in the complaint.\n\nThe release urges investors who purchased shares between March 24, 2025, and March 12, 2026, to contact the firm before the July 6, 2026, lead plaintiff deadline.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"pre_decline_price":2.76,"decline_percentage":"83%","post_decline_price":0.48,"single_day_decline_per_share":2.28}},"quotedText":"Corporate officers have a duty to ensure their companies' public statements are accurate and complete. When executives certify SEC filings and make affirmative statements about clinical trial progress, they accept personal responsibility for the accuracy of those representations.","namedEntities":{"people":[{"name":"Marc Voigt","role":"CEO"},{"name":"Frédéric Triebel","role":"Chief Scientific Officer"},{"name":"Stephan Winckels","role":"Chief Medical Officer"},{"name":"Joseph E. Levi","role":"Attorney"}],"products":["TACTI-004"],"companies":[{"name":"Immutep Limited","ticker":"IMMP","relationship":"defendant"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.28","context":"per-share loss from single-day decline"},{"amount":"$2.76","context":"pre-decline share price"},{"amount":"$0.48","context":"post-decline share price"}]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by SueWallSt (Levi & Korsinsky). It contains standard lead-plaintiff deadline reminders and contact CTAs. No new disclosure from the issuer, no certified class, and no settlement announced."},"tickerRelevance":{"others":[],"primary":"IMMP"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","sectorWeight":"biotech_litigation_noise","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt issued a press release soliciting investors in Immutep Limited (IMMP) to join a securities class action lawsuit.\n\nThe firm highlights that three senior executives—CEO Marc Voigt, CSO Frédéric Triebel, and CMO Stephan Winckels—are named as individual defendants in the complaint.\n\nThe release urges investors who purchased shares between March 24, 2025, and March 12, 2026, to contact the firm before the July 6, 2026, lead plaintiff deadline.","key_figures":{"customDimensions":{"pre_decline_price":2.76,"decline_percentage":"83%","post_decline_price":0.48,"single_day_decline_per_share":2.28}},"named_entities":{"people":[{"name":"Marc Voigt","role":"CEO"},{"name":"Frédéric Triebel","role":"Chief Scientific Officer"},{"name":"Stephan Winckels","role":"Chief Medical Officer"},{"name":"Joseph E. Levi","role":"Attorney"}],"products":["TACTI-004"],"companies":[{"name":"Immutep Limited","ticker":"IMMP","relationship":"defendant"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.28","context":"per-share loss from single-day decline"},{"amount":"$2.76","context":"pre-decline share price"},{"amount":"$0.48","context":"post-decline share price"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-21T13:06:17.364Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","sectorWeight":"biotech_litigation_noise","issuerAuthored":false}},"durationMs":21955,"modelName":"george-droid-qwen-72b"}}